tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

IMMX Stock Latest News

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Press ReleasesImmix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
16h ago
IMMX
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
PremiumPress Releases
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
23d ago
IMMX
Immix Biopharma announces three more sites for NEXICART-2 trial
PremiumThe Fly
Immix Biopharma announces three more sites for NEXICART-2 trial
23d ago
IMMX
Immix Biopharma awarded $8M CLIN2 grant
PremiumThe Fly
Immix Biopharma awarded $8M CLIN2 grant
2M ago
IMMX
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
PremiumPress Releases
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
2M ago
IMMX
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
PremiumPress ReleasesImmix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
2M ago
IMMX
Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201
Premium
The Fly
Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201
2M ago
IMMX
Immix Biopharma initiated with a Buy at H.C. Wainwright
Premium
The Fly
Immix Biopharma initiated with a Buy at H.C. Wainwright
3M ago
IMMX
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
PremiumPress Releases
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
3M ago
IMMX
Immix Biopharma Shareholders Back Growth and Governance Changes
PremiumCompany Announcements
Immix Biopharma Shareholders Back Growth and Governance Changes
3M ago
8K
IMMX
Immix Biopharma announces NXC-201 relapsed/refractory AL Amyloidosis data
PremiumThe Fly
Immix Biopharma announces NXC-201 relapsed/refractory AL Amyloidosis data
4M ago
IMMX
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
PremiumPress Releases
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
4M ago
IMMX
Immix Biopharma management to meet with B. Riley
PremiumThe FlyImmix Biopharma management to meet with B. Riley
4M ago
IMMX
Immix Biopharma management to meet with B. Riley
Premium
The Fly
Immix Biopharma management to meet with B. Riley
5M ago
IMMX
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Premium
Press Releases
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
5M ago
IMMX
Immix Biopharma: EC grants orphan drug designation to NXC-201
PremiumThe Fly
Immix Biopharma: EC grants orphan drug designation to NXC-201
5M ago
IMMX
Immix Biopharma on Track to Dose NXC-201 Patients in United States
PremiumPress Releases
Immix Biopharma on Track to Dose NXC-201 Patients in United States
5M ago
IMMX
Immix Biopharma says ‘on track’ to dose NXC-201 patients in U.S.
PremiumThe Fly
Immix Biopharma says ‘on track’ to dose NXC-201 patients in U.S.
5M ago
IMMX
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
PremiumPress Releases
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
5M ago
IMMX
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
PremiumPress ReleasesImmix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
6M ago
IMMX
Immix announces Memorial Sloan Kettering as lead site for NXC-201 trial
Premium
The Fly
Immix announces Memorial Sloan Kettering as lead site for NXC-201 trial
6M ago
IMMX
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Premium
Press Releases
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
7M ago
IMMX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >